ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • seronegative spondyloarthropathy and spondylarthritis
  • seronegative spondyloarthropathy and treatment guidlelines
  • Serositis
  • SEVERE
  • severe joint pain
  • severity
  • severity and activities of daily living (ADL)
  • severity and Gene Expression
  • severity and outcomes
  • severity and sex bias
  • severity and socioeconomic status
  • severity and spondylarthritis
  • severity and statistical methods
  • severity and synovial cells
  • severity and synovial fluid
  • severity and systemic lupus erythematosus (SLE)
  • severity and systemic sclerosis
  • severity and tofacitinib
  • severity and treatment
  • severity and vasculitis
  • sex
  • sex and physician data
  • sex and race/ethnicity
  • sex bias
  • sex bias and health outcome
  • sex bias and race
  • sex bias and spondylarthritis
  • sex bias and surgery
  • sex bias and systemic lupus erythematosus (SLE)
  • sex bias and systemic sclerosis
  • sex bias and toll-like receptors
  • sex bias and treatment
  • sex bias and tumor necrosis factor (TNF)
  • sex bias and women's health
  • sex hormones
  • sex hormones and pain
  • sex hormones and systemic lupus erythematosus (SLE)
  • sex hormones and toll-like receptors
  • sexual and lymphopenia
  • Sexual Function
  • sexual health
  • Sexuality
  • Sexuality and fibromyalgia
  • Sexuality and rheumatoid arthritis (RA)
  • Sexuality and systemic lupus erythematosus (SLE)
  • SF-36 and axSpA
  • SF36
  • SH3BP2
  • shared decisionmaking
  • Shared dicision making
  • shared dicision making and systemic lupus erythematosus (SLE)
  • shared dicision making and treatment
  • shared dicision making and treatment guidlelines
  • shared dicision making and treatment options
  • shared dicision making and vasculitis
  • Shingrix
  • shock
  • shoulder
  • shoulder disorders
  • shoulder disorders and steroids
  • shoulder disorders and tendonitis/bursitis
  • shoulder disorders and tocilizumab
  • shoulder disorders and ultrasound
  • Shoulder Pain
  • Shoulder Pain and shoulder disorders
  • Shoulder Pain and steroids
  • Shoulder Pain and therapy
  • Shoulder Pain and ultrasonography
  • SHR4640
  • sialic acid and rheumatoid arthritis (RA)
  • sialoadenitis and tobacco use
  • sialoadenitis and transcription factor
  • sialoadenitis and ultrasonography
  • SIBO
  • SICCA
  • SICCA and MALT lymphoma
  • Sick leave
  • Side effect
  • SIGLEC-1
  • signal transduction
  • signal transduction and spondylarthritis
  • signal transduction and synovial cells
  • signal transduction and systemic lupus erythematosus (SLE)
  • signal transduction and systemic sclerosis
  • signal transduction and therapeutic targeting
  • signal transduction and thrombosis
  • signal transduction and tolerance
  • signal transduction and toll-like receptors
  • signal transduction and transcription factor
  • signal transduction and transforming growth factor
  • signal transduction and tumor necrosis factor (TNF)
  • signal transduction and type II collagen
  • silent lupus nephritis
  • Simulation Model
  • single cell rna seq
  • single cell RNA sequencing
  • single cell sequencing
  • Single-ascending dose
  • sirt1 and ampk
  • site and activity score
  • sitting
  • six-minute walk test
  • Sjӧgrens
  • Sjögren's Syndrome
  • Sjogren's syndrome
  • Sjögren's syndrome
  • Sjogren's syndrome and abatacept
  • Sjogren's syndrome and activity score
  • Sjogren's syndrome and administrative databases
  • Sjogren's syndrome and ankylosing spondylitis (AS)
  • Sjogren's syndrome and anti-centromere antibodies (ACA)
  • Sjogren's syndrome and auto-immunity
  • Sjogren's syndrome and autoantibodies
  • Sjogren's syndrome and autoantigens
  • Sjogren's syndrome and autoimmune diseases
  • Sjogren's syndrome and belimumab
  • Sjogren's syndrome and biomarkers
  • Sjogren's syndrome and biopsies
  • Sjogren's syndrome and cancer
  • Sjogren's syndrome and cardiovascular disease
  • Sjogren's syndrome and classification criteria
  • Sjogren's syndrome and clinical practice
  • Sjogren's syndrome and clinical research
  • Sjogren's syndrome and clinical trials
  • Sjogren's syndrome and cognitive dysfunction
  • Sjogren's syndrome and combination therapies
  • Sjogren's syndrome and complement
  • Sjogren's syndrome and computed tomography (CT)
  • Sjogren's syndrome and cryoglobulinemia
  • Sjogren's syndrome and cytokines
  • Sjogren's syndrome and dendritic cells
  • Sjogren's syndrome and diagnosis
  • Sjogren's syndrome and epidemiologic methods
  • Sjogren's syndrome and epigenetics
  • Sjogren's syndrome and ESSPRI
  • Sjogren's syndrome and ethnic studies
  • Sjogren's syndrome and extraarticular manifestations
  • Sjogren's syndrome and fatigue
  • Sjogren's syndrome and fibroblasts
  • Sjogren's syndrome and fibromyalgia
  • Sjogren's syndrome and fracture risk
  • Sjogren's syndrome and genetics
  • Sjogren's syndrome and genomics
  • Sjogren's syndrome and gynecologic issues
  • Sjogren's syndrome and hydroxychloroquine
  • Sjogren's syndrome and immunosuppressants
  • Sjogren's syndrome and inflammasome activation
  • Sjogren's syndrome and innate immunity
  • Sjogren's syndrome and interferons
  • Sjogren's syndrome and interleukins (IL)
  • Sjogren's syndrome and interstitial lung disease
  • Sjogren's syndrome and lung
  • Sjogren's syndrome and Lung Disease
  • Sjogren's syndrome and major histocompatibility complex (MHC)
  • Sjogren's syndrome and malignancy
  • Sjogren's syndrome and mast cells
  • Sjogren's syndrome and mesenchymal stem cells
  • Sjogren's syndrome and methylation
  • Sjogren's syndrome and mTor
  • Sjogren's syndrome and natural killer (NK) cells
  • Sjogren's syndrome and neonatal lupus
  • Sjogren's syndrome and neurologic involvement
  • Sjogren's syndrome and neuropathy
  • Sjogren's syndrome and oral
  • Sjogren's syndrome and outcome measures
  • Sjogren's syndrome and pathogenesis
  • Sjogren's syndrome and pediatric rheumatology
  • Sjogren's syndrome and plasma cells
  • Sjogren's syndrome and polymorphism
  • Sjogren's syndrome and positron emission tomography (PET)
  • Sjogren's syndrome and prognostic factors
  • Sjogren's syndrome and proteomics
  • Sjogren's syndrome and pulmonary complications
  • Sjogren's syndrome and quality of life
  • Sjogren's syndrome and questionnaires
  • Sjogren's syndrome and recruiting
  • Sjogren's syndrome and registry
  • Sjogren's syndrome and regulatory cells
  • Sjogren's syndrome and rheumatoid arthritis (RA)
  • Sjogren's syndrome and risk
  • Sjogren's syndrome and rituximab
  • Sjogren's syndrome and safety
  • Sjogren's syndrome and salivary gland
  • Sjogren's syndrome and salivary hypofunction
  • Sjogren's syndrome and sex bias
  • Sjogren's syndrome and sex hormones
  • Sjogren's syndrome and sialoadenitis
  • Sjogren's syndrome and sicca symptom
  • Sjogren's syndrome and Sjӧgrens
  • Sjogren's syndrome and small fiber neuropathy
  • Sjogren's syndrome and systemic lupus erythematosus (SLE)
  • Sjogren's syndrome and systemic sclerosis
  • Sjogren's syndrome and T cells
  • Sjogren's syndrome and tocilizumab
  • Sjogren's syndrome and transcriptional regulation
  • Sjogren's syndrome and treatment
  • Sjogren's syndrome and treatment options
  • Sjogren's syndrome and ultrasonography
  • Sjogren's syndrome and ultrasound
  • Sjogren's syndrome and vaccines
  • First |
  • « Previous Page
  • 54
  • 55
  • 56
  • 57
  • 58
  • [59]
  • 60
  • 61
  • 62
  • 63
  • 64
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology